This month, twenty years ago, a pioneering clinical trial in Alberta marked a major advancement in islet transplantation for the treatment of type 1 diabetes (T1D).
JDRF Canada welcomes new Chief Scientific Officer, Dr. Sarah Linklater
We are pleased to announce Dr. Sarah Linklater has been appointed as Chief Scientific Officer (CSO).
New test offers better insight into genetic risk of type 1 diabetes in people of African descent
Recently, a team of researchers in the United States developed a test to identify individuals of African descent who are more likely to get the disease.
A JDRF legacy lives on with the Dr. Robert Goldstein Award
Dr. Esteban N. Gurzov, a talented young scientist from Brussels, Belgium, was recently named the first recipient of JDRF’s Dr. Robert Goldstein Award.
Paying it forward through research: From trial participant to T1D advocate
From Walk participant to trial participant to T1D advocate, here is Ash Hunkin’s story.
New Quebec registry tracks hypoglycemia among diabetes patients to help reduce risks
Dr. Rémi Rabasa-Lhoret, a JDRF-funded endocrinologist at the Institut de recherches cliniques de Montréal best known for his work on the artificial pancreas, is overseeing the initiative to collect data for the Quebec-wide registry of people with T1D in order to track the incidence of hypoglycemic episodes and allow patients to better manage their disease.
Studying the role of Vitamin D in the risk of type 1 diabetes
Does Vitamin D play a role in developing type 1 diabetes (T1D)?
Exploring oral therapy to safeguard beta cells and treat type 1 diabetes
Administering insulin on a daily basis can be a tedious task, particularly among individuals newly diagnosed with type 1 diabetes (T1D). To mitigate this, researchers are currently experimenting with islet (insulin-producing cells) transplantation as a promising therapy that eliminates the need for insulin injections.
Sernova recruits first subjects for its Cell PouchTM diabetes clinical trial
Since 2016, JDRF and Sernova Corp., a clinical-stage regenerative medicine company, have been collaborating on innovative technology to treat hypoglycaemia (low sugar) unawareness in patients with severe T1D.
#AccessForAll: We’re demanding affordable and accessible coverage for everyone living with type 1 diabetes
JDRF is excited to be launching our new Access for All campaign this week to urge provincial and territorial governments, insurers and employers to help make life-changing technologies affordable and accessible for Canadians with type 1 diabetes.
Drug approved for treatment of psoriasis and Crohn’s disease may protect beta cell transplants
Currently, JDRF-funded researcher, Dr. Jan Dutz, and his team at the University of British Columbia are investigating whether the administration of an antibody called ustekinumab among adults and children newly diagnosed with T1D can protect insulin-producing beta cells.
The impact of protein on insulin dosing
Currently, JDRF-funded researcher, Dr. Jan Dutz, and his team at the University of British Columbia are investigating whether the administration of an antibody called ustekinumab among adults and children newly diagnosed with T1D can protect insulin-producing beta cells.